Braxia Scientific(OTC) BRAXF

Market Cap$300.00

Since IPO (2020)-100%

5 Year-100%

1 Year+0%

1 Month+0%

$0.00

+0%

+0.00Today

Braxia Scientific last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-07-23

Braxia Scientific stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-07-16
1 month	+0%	USD 0.00	2026-06-23
3 month	+0%	USD 0.00	2026-04-24
Year to date	+0%	USD 0.00	2025-12-31
1 year	+0%	USD 0.00	2025-07-22
3 year	-99.99%	USD 0.01	2023-07-24
5 year	-100%	USD 0.23	2021-07-23
Since inception	-100%	USD 0.70	2020-05-01

Braxia Scientific Financials at a Glance

Market Cap

$300.00

Revenue (TTM)

CA$2.21M

Net Income (TTM)

-CA$9.64M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-62.79 (Low)

Dividend

$0.00

Beta (Volatility)

-62.79 (Low)

Price

$0.00

Volume

Open

$0.00

Price

$0.00

Volume

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Mar 17, 2025

Dividend

$0.00

Beta (Volatility)

-62.79 (Low)

Price

$0.00

Volume

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Mar 17, 2025

BRAXF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Braxia Scientific

Braxia Scientific Corp. is a biotechnology company focused on medical research and the provision of innovative ketamine therapies for individuals suffering from depression and related conditions. The company is also engaged in the development of novel pharmaceutical compounds and delivery methods, particularly in the psychedelic space.

Products and Services

Ketamine therapy clinics for mental health treatment
Research and development of psychedelic compounds
Innovative delivery methods for therapeutic substances

Growth Outlook

Expansion of clinic network to meet rising demand for mental health services
Increasing interest in psychedelic therapies among healthcare providers
Potential partnerships for drug development and commercialization

Financial Highlights

Recent quarterly revenue of CAD 492,445, showing resilience in challenging market conditions
Trailing twelve months (TTM) revenue of CAD 2,207,731, indicating steady growth
Current ratio of 1.00, reflecting adequate liquidity to meet short-term obligations

Braxia Scientific Corp. operates in a rapidly evolving sector, with a focus on addressing significant mental health challenges through innovative therapies. The company's commitment to research and development positions it well to capitalize on the growing acceptance of psychedelic treatments. Recent financial performance demonstrates resilience, with a notable revenue stream and a solid liquidity position. As the demand for mental health services continues to rise, Braxia Scientific is poised for potential growth and expansion in the coming years.

AI Generated • Jul 16, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

CEO

Roger S. McIntyre, MD

Website

www.braxiascientific.com

Headquarters

Mississauga, ON L5G 3H4, CA

BRAXF Financials

Key Financial Metrics (TTM)

Gross Margin

9.12%

Operating Margin

-397.00%

Net Income Margin

-697.48%

Return on Equity

-248.72%

Return on Capital

-412.84%

Return on Assets

-338.34%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$300.00

Shares Outstanding

283.28M

Volume

Avg. Volume

14.27K

Financials (TTM)

Gross Profit

-CA$1.05M

Operating Income

-CA$4.32M

EBITDA

-CA$3.85M

Operating Cash Flow

-CA$2.56M

Capital Expenditure

-CA$42.65K

Free Cash Flow

-CA$2.60M

Cash & ST Invst.

CA$128.34K

Total Debt

CA$636.64K

Braxia Scientific Performance Analysis

Braxia Scientific annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-03-31	CAD 1,186,038	N/A
2023	2023-03-31	CAD 1,424,291	20.1%

Braxia Scientific sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2023-03-31	6.8%
Q1	2023-06-30	14.9%
Q2	2023-09-30	-1.0%
Q3	2023-12-31	-17.1%

Braxia Scientific annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-03-31	CAD -0.06	N/A
2023	2023-03-31	CAD -0.04	-21.2%

Braxia Scientific sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2023-03-31	-222.2%
Q1	2023-06-30	89.7%
Q2	2023-09-30	66.7%
Q3	2023-12-31	-240.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q3 2024YOY CHG

Revenue

CA$492.45K

+0.7%

Gross Profit

CA$81.98K

+108.7%

Gross Margin

16.65%

N/A

Market Cap

$300.00

N/A

Market Cap/Employee

$60.00

N/A

Employees

N/A

Net Income

-CA$907.05K

+58.2%

EBITDA

-CA$807.51K

+63.8%

Quarterly Fundamentals

Name

Q3 2024YOY CHG

Total Cash

CA$128.34K

-91.4%

Total Debt

CA$636.64K

+305.0%

Accounts Receivable

CA$91.03K

-58.0%

Inventory

CA$0.00

-100.0%

Long Term Debt

CA$501.04K

+270.5%

Short Term Debt

CA$135.60K

+74.5%

Return on Assets

-3.38%

N/A

Return on Invested Capital

-4.31%

N/A

Free Cash Flow

-CA$541.68K

+85.1%

Operating Cash Flow

-CA$532.56K

+85.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

AVXTAVAX Technologies, Inc.

AVXTAVAX Technologies, Inc.$0.00+0.00%

ARYCArrayit Corporation

ARYCArrayit Corporation$0.00+0.00%

DNAGDNAPrint Genomics, Inc.

DNAGDNAPrint Genomics, Inc.$0.00+0.00%

TRCNFTransnational Cannabis Ltd.

TRCNFTransnational Cannabis Ltd.$0.00+0.00%

PBLAPanbela Therapeutics, Inc.

PBLAPanbela Therapeutics, Inc.$0.01+0.00%

USRMU.S. Stem Cell, Inc.

USRMU.S. Stem Cell, Inc.$0.00+0.00%

MOBOMobile Lads Corp.

MOBOMobile Lads Corp.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SOFISoFi Technologies

SOFISoFi Technologies$15.25-0.09%

INTCIntel

INTCIntel$81.88-0.05%

NVDANvidia

NVDANvidia$190.01-0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$57.75-0.06%

FFord Motor Company

FFord Motor Company$15.28+0.02%

NOKNokia

NOKNokia$8.41-0.06%

JBLUJetBlue Airways

JBLUJetBlue Airways$5.72-0.05%

Questions About BRAXF

What is the current price of Braxia Scientific?

Braxia Scientific is trading at $0.00 per share.

What is the 52-week range for Braxia Scientific?

Over the past 52 weeks, Braxia Scientific has traded between $0.00 and $0.00.

How much debt does Braxia Scientific have?

As of the most recent reporting period, Braxia Scientific reported total debt of CA$112.21K.

How much cash does Braxia Scientific have on hand?

Braxia Scientific reported CA$1.08M in cash and cash equivalents in its most recent financial results.

What is Braxia Scientific’s dividend yield?

Braxia Scientific does not currently have a dividend yield.

Braxia Scientific(OTC) BRAXF

Braxia Scientific Financials at a Glance

BRAXF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Braxia Scientific

BRAXF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Braxia Scientific Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About BRAXF

What is the current price of Braxia Scientific?

What is the 52-week range for Braxia Scientific?

How much debt does Braxia Scientific have?

How much cash does Braxia Scientific have on hand?

What is Braxia Scientific’s dividend yield?

Premium Investing Services